RESUMO
An open study was carried out in general practice on 678 hypertensive patients being treated with a beta-blocker but who still had resting diastolic blood pressures greater than 100 mmHg. Previous treatment was stopped and substituted with 1 or 2 tablets daily of a fixed combination product containing 160 mg oxprenolol hydrochloride in a sustained-release formulation plus 0.25 mg cyclopenthiazide per tablet. After 4-weeks' treatment on this regimen, blood pressure levels fell significantly, from 179/108 mmHg to 155/93 mmHg, without any increase in the reporting of unpleasant side-effects.
Assuntos
Ciclopentiazida/uso terapêutico , Hipertensão/tratamento farmacológico , Oxprenolol/uso terapêutico , Inibidores de Simportadores de Cloreto de Sódio/uso terapêutico , Adulto , Idoso , Pressão Sanguínea/efeitos dos fármacos , Ciclopentiazida/efeitos adversos , Preparações de Ação Retardada , Diuréticos , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Oxprenolol/efeitos adversos , Pulso Arterial/efeitos dos fármacosRESUMO
In a three-week study of 10,000 general practice patients with depressive illness, a once nightly dose of maprotiline 75 mg (Ludiomil) was effective therapy in three-quarters of the patients who completed the study. At this dose the drug was well tolerated, and troublesome side-effects presented in only a small percentage of patients. Drowsiness was the most commonly reported side-effect, and the main reason for stopping treatment. The drug was acceptable to most physicians, and in this study was used in a wide age range of patients and over a broad spectrum of depressive illness.
Assuntos
Antracenos/uso terapêutico , Depressão/tratamento farmacológico , Maprotilina/uso terapêutico , Adulto , Idoso , Feminino , Humanos , Masculino , Maprotilina/administração & dosagem , Maprotilina/efeitos adversos , Pessoa de Meia-IdadeRESUMO
In a three-week study of 10,000 general practice patients with depressive illness, a single dose of maprotiline 75 mg at night was effective therapy in three-quarters of the patients who completed the study. At this dose the drug was well tolerated, and troublesome side-effects presented in only a small percentage of patients. Drowsiness was the most commonly reported side-effect, and the main reason for withdrawal of treatment. The drug was acceptable to most physicians, and in this study was used in a wide range of patients and over a broad spectrum of depressive illness.